Gefapixant

Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough.^[1] It acts as an antagonist of the P2RX3 receptor.^[2][3][4]

Gefapixant

Clinical data
Trade names	Lyfnua
Other names	MK-7264
ATC code	R05DB29 (WHO)
Legal status
Legal status	EU: Rx-only[1]
Identifiers
IUPAC name 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide
CAS Number	1015787-98-0
PubChem CID	24764487
DrugBank	DB15097
ChemSpider	58828660
UNII	6K6L7E3F1L
KEGG	D11349
ChEMBL	ChEMBL3716057
CompTox Dashboard (EPA)	DTXSID401337212
ECHA InfoCard	100.258.106
Chemical and physical data
Formula	C14H19N5O4S
Molar mass	353.40 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)C1=CC(=C(C=C1OC2=CN=C(N=C2N)N)S(=O)(=O)N)OC
InChI InChI=1S/C14H19N5O4S/c1-7(2)8-4-10(22-3)12(24(17,20)21)5-9(8)23-11-6-18-14(16)19-13(11)15/h4-7H,1-3H3,(H2,17,20,21)(H4,15,16,18,19) Key:HLWURFKMDLAKOD-UHFFFAOYSA-N

It was authorized for medical use in the European Union in September 2023.^[1]

Medical uses

Gefapixant is indicated for the treatment of refractory or unexplained chronic cough.^[1]

Society and culture

Names

It was named in honour of Geoff Burnstock.^[5]